"I am glad that taking part in a trial might help others on their own cancer journey.”
A trial comparing erlotinib with docetaxel for non small cell lung cancer that has got worse despite chemotherapy (EMPHASIS-lung)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial compared erlotinib and docetaxel for a type of non small cell lung cancer called squamous cell cancer. It was for people whose cancer had got worse despite having treatment with a platinum chemotherapy drug.
More about this trial
Doctors sometimes use chemotherapy for non small cell lung cancer (NSCLC) that has spread outside the lung or to another part of the body. They often use a platinum chemotherapy drug such as cisplatin or carboplatin.
As well as comparing these 2 drugs, this trial also looked at a test called VeriStrat. This looks for certain proteins in blood samples. Everybody taking part in this trial had the test before they started treatment.
Depending on the proteins in their blood, people were classed as VeriStrat good or VeriStrat poor. The research team hoped it would help predict how well treatment would work.
The aims of this trial were to see:
- whether docetaxel or erlotinib is better for people who have a type of non small cell lung cancer called squamous cell cancer
- how useful the VeriStrat test is
Summary of results
The results showed that there was little difference between erlotinib and docetaxel for advanced non small cell lung cancer. But that the VeriStrat test may help predict who was likely to live longer.
This trial recruited 80 people with a type of non small cell lung cancer called squamous cell cancer. Everyone taking part had already had treatment that included platinum chemotherapy.
The research team had hoped more people would join the trial. But they found it quite difficult to recruit people so they closed the trial earlier than planned.
Of the 80 people who took part, there were:
- 38 in the erlotinib group – 28 VeriStrat good and 10 VeriStrat poor
- 42 in the docetaxel group – 30 VeriStrat good and 12 VeriStrat poor
The research team looked at how long it was before the cancer started to grow again. They found it was similar in the different groups.
They also looked at how long people lived for. They found there wasn’t much difference between the two treatments. But there was a difference between the two VeriStrat groups.
For the group classed as VeriStrat good it was:
- 7.8 months for those who had docetaxel
- 8.4 months for those who had erlotinib
For the group classed as VeriStrat poor it was:
- 4.4 months for those who had docetaxel
- 5.2 months for those who had erlotinib
When they looked at how many people had died in both treatment groups, they found it was nearly 7 out of 10 people (69%) who were VeriStrat good. And more than 9 out of 10 people (91%) who were VeriStrat poor.
Most of the people taking part had at least one side effect:
- 36 out of 38 people who had erlotinib
- 39 out of 41 people who had docetaxel
Some of the side effects were mild or short lived. But 26 people had a more serious side effect:
- 7 people who had erlotinib
- 19 people who had docetaxel
The research team concluded that there was no difference in how well erlotinib and docetaxel worked for advanced non small cell lung cancer. But that people classed as VeriStrat good tended to live longer than those classed as VeriStrat poor.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Yvonne Summers
European Thoracic Oncology Platform (ETOP)
NIHR Clinical Research Network: Cancer